Relmada Therapeutics, Inc. (RLMD)
3.26
-0.02
(-0.61%)
USD |
NASDAQ |
Oct 07, 16:00
3.26
0.00 (0.00%)
After-Hours: 20:00
Relmada Therapeutics Net Income (Quarterly) : -12.91M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -12.91M |
| March 31, 2026 | -19.05M |
| December 31, 2025 | -19.87M |
| September 30, 2025 | -10.09M |
| June 30, 2025 | -9.866M |
| March 31, 2025 | -17.56M |
| December 31, 2024 | -18.66M |
| September 30, 2024 | -21.73M |
| June 30, 2024 | -17.77M |
| March 31, 2024 | -21.83M |
| December 31, 2023 | -25.17M |
| September 30, 2023 | -22.00M |
| June 30, 2023 | -25.30M |
| March 31, 2023 | -26.32M |
| December 31, 2022 | -37.94M |
| September 30, 2022 | -39.42M |
| June 30, 2022 | -39.94M |
| March 31, 2022 | -39.75M |
| December 31, 2021 | -34.38M |
| September 30, 2021 | -42.61M |
| June 30, 2021 | -26.55M |
| March 31, 2021 | -22.22M |
| December 31, 2020 | -20.76M |
| September 30, 2020 | -16.90M |
| June 30, 2020 | -11.12M |
| Date | Value |
|---|---|
| March 31, 2020 | -10.67M |
| June 30, 2019 | -4.123M |
| March 31, 2019 | -2.686M |
| December 31, 2018 | -7.129M |
| September 30, 2018 | -3.380M |
| June 30, 2018 | -3.350M |
| March 31, 2018 | -3.202M |
| December 31, 2017 | -1.427M |
| September 30, 2017 | -0.9817M |
| June 30, 2017 | -1.634M |
| March 31, 2017 | -1.982M |
| December 31, 2016 | -1.031M |
| September 30, 2016 | -1.641M |
| June 30, 2016 | -3.317M |
| March 31, 2016 | -1.860M |
| December 31, 2015 | -2.461M |
| September 30, 2015 | 4.663M |
| June 30, 2015 | 6.042M |
| March 31, 2015 | -2.463M |
| December 31, 2014 | 5.455M |
| September 30, 2014 | -29.84M |
| February 28, 2014 | -0.0031M |
| September 30, 2013 | -1.565M |
| August 31, 2013 | -0.0124M |
| May 31, 2013 | -0.0195M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 23.00M |
| Corcept Therapeutics, Inc. | 42.14M |
| Veru, Inc. | -6.988M |
| Johnson & Johnson | 5.534B |
| Eli Lilly & Co. | 7.095B |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 12.91M |
| EPS Diluted (Quarterly) | -0.1149 |
| Enterprise Value | 132.15M |
| Earnings Yield | -28.53% |
| Normalized Earnings Yield | -28.47 |